title: Risks and benefits of available treatments for adult ADHD.
abstract: Several pharmacotherapeutic options, both FDA-approved and off-label, exist for the treatment of adult ADHD. The most commonly used agents include several stimulants and atomoxetine, which have demonstrated significant, though similar, efficacy for ADHD versus placebo. Treatment should be selected according to patient comorbidity profiles, cardiovascular risks, and risk of abuse of prescription medications. In this activity, treatments for ADHD with and without comorbidity are discussed, including mechanisms of action, safety risks, and the potential for substance abuse. Implementing psychosocial education in conjunction with pharmacotherapy is recommended.
authors: Division of Child and Adolescent Psychiatry, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA.
authors: Jeffrey H
authors: JH
authors: Newcorn
mesh_terms: D000328:Adult; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D010353:Patient Education as Topic; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment
chemical_list: D000697:Central Nervous System Stimulants; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride